It's been a rough couple of months for GW Pharmaceuticals (NASDAQ: GWPH). The stock sank in February after the biotech reported a major disappointment for its cannabidivarin (CBDV) compound GWP42006 in a phase 2a clinical study targeting treatment of focal seizures. But the cannabinoid-focused biotech announced important good news last week related to its lead product Epidiolex.